Published Research Evidence The evidence base differs dramatically in size and quality between these approaches
For more information, please reach out to express interest in being a potential guest on the Ageless and Timeless podcast or to be featured in the TopDoctor Magazine Ageless and Timeless column with Michele Hughes
C.BerthoudH
pediatric effectiveness, including Recruitment ongoing observational patients prescribed follow up on neoplasms until Q1 2028 Skytrofa and type 2 diabetes Minimum follow-up of development five years INSIGHTS-GHT Germany Multiple growth Prospective 33 participating German Long-term efficacy and Initiated in 2022 hormone products, observational, centers safety, including patient- Minimum follow-up of including Skytrofa cross-product focused outcomes such three years registry as quality of life Introduction P|ESG Approach Impact Ambitions 30 2025 and 2026 Corporate Responsibility and P|ESG Ambitions 2025 Ambitions Status Description 2026 Ambitions Significant regulatory developments, including Review the material impacts, risks and the evolving CSRD and ESRS requirements, led In opportunities related to our patients as us to pause our DMA work to ensure alignment progress part of our 2025 DMA

The new results from REDEFINE-1 show that cagrilintide can help people lose a meaningful amount of weight and is generally well tolerated
No side effects, hunger under control and down 8 pounds